Philip Levin, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1528063567
Payments from drug & device makers
Across 788 payments — averaging $891.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$325K
- Amgen$196K
- Merck$43K
- Mannkind Corporation$24K
- Johnson & Johnson$22K
- Sanofi-aventis U.S. LLC$18K
- plus $75K from 34 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$250
What the payments were for
- Consulting fees$22,5405%
- Speaking & faculty fees$409,44984%
- Travel & lodging$45,5049%
- Food & beverage$10,9892%
- Education$300%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 345 | $325,296 |
| Amgen(2 entities) | 66 | $195,649 |
| Merck | 46 | $42,677 |
| Mannkind Corporation | 46 | $23,712 |
| Johnson & Johnson | 31 | $22,083 |
| Sanofi-aventis U.S. LLC | 46 | $18,035 |
| Dexcom, Inc. | 10 | $15,041 |
| Eisai Inc. | 2 | $13,706 |
| Bayer | 9 | $10,561 |
| Boehringer Ingelheim | 33 | $10,478 |
| Insulet Corporation | 8 | $4,044 |
| AbbVie | 19 | $3,882 |
| Novo Nordisk | 38 | $3,416 |
| Shire North American Group Inc | 5 | $3,192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $3,180 |
| Novartis | 4 | $2,009 |
| Novo Nordisk AS | 2 | $1,979 |
| Eli Lilly | 1 | $1,067 |
| Mylan Technologies Inc. | 2 | $750 |
| Corcept Therapeutics | 15 | $365 |
| Amarin Pharma, Inc. | 6 | $212 |
| AstraZeneca(2 entities) | 12 | $201 |
| Amneal Pharmaceuticals LLC | 6 | $110 |
| Abbott | 4 | $101 |
| Cequr Corporation | 2 | $73 |
| Radius Health, Inc. | 3 | $73 |
| Antares Pharma, Inc. | 4 | $66 |
| Almatica Pharma LLC | 2 | $54 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Nevro Corp. | 2 | $42 |
| Medtronic(2 entities) | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $34 |
| BD | 1 | $33 |
| Valeritas, Inc. | 1 | $33 |
| Lifescan, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Companion Medical, Inc. | 3 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Pfizer | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$702,345 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 138 | $173,767 |
| TrulicityDulaglutide | 61 | $109,468 |
| OzempicSemaglutide | 55 | $101,147 |
| MounjaroTirzepatide | 64 | $86,429 |
| JanuviaSitagliptin Phosphate | 37 | $55,131 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $47,718 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $28,537 |
| FarxigaDapagliflozin Propanediol | 14 | $22,945 |
| TradjentaLinagliptin | 21 | $21,251 |
| Novolog FlexpenInsulin Aspart | 37 | $12,098 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $10,182 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $7,851 |
| SynthroidLevothyroxine Sodium | 44 | $4,456 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $4,246 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $3,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $325,296 | $195,897125 claims |
| Boehringer IngelheimJardiance, Tradjenta | $10,478 | $195,017159 claims |
| Novo NordiskOzempic | $3,416 | $101,14755 claims |
| MerckJanuvia | $42,677 | $55,13137 claims |
| AstraZenecaFarxiga | $201 | $22,94514 claims |
| AbbVieSynthroid | $3,882 | $4,45644 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $110 | $1,468129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Jean ParkBaltimore$3.7M
- Ilias SpanakisBaltimore$2.6M
- Roberto SalvatoriBaltimore$403K
- Thomas DonnerBaltimore$197K
- Adrian DobsBaltimore$190K
- Todd BrownBaltimore$143K
- Nowreen HaqBaltimore$85K
- Nanette SteinleBaltimore$74K
- Paul SackBaltimore$69K
- Asif MohamedBaltimore$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.